Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis.

MLA

Washino, Satoshi, et al. “Association between Immune-Related Adverse Events and Survival in Patients with Renal Cell Carcinoma Treated with Nivolumab plus Ipilimumab: Immortal Time Bias-Corrected Analysis.” International Journal of Clinical Oncology, vol. 28, no. 12, Dec. 2023, pp. 1651–58. EBSCOhost, https://doi.org/10.1007/s10147-023-02406-x.

APA

Washino, S., Shirotake, S., Takeshita, H., Inoue, M., Miura, Y., Hyodo, Y., Kagawa, M., Izumi, K., Oyama, M., Kawakami, S., Saito, K., Matsuoka, Y., Taniuchi, S., Shintani, A., & Miyagawa, T. (2023). Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis. International Journal of Clinical Oncology, 28(12), 1651–1658. https://doi.org/10.1007/s10147-023-02406-x

Chicago

Washino, Satoshi, Suguru Shirotake, Hideki Takeshita, Masaharu Inoue, Yuji Miura, Yoji Hyodo, Makoto Kagawa, et al. 2023. “Association between Immune-Related Adverse Events and Survival in Patients with Renal Cell Carcinoma Treated with Nivolumab plus Ipilimumab: Immortal Time Bias-Corrected Analysis.” International Journal of Clinical Oncology 28 (12): 1651–58. doi:10.1007/s10147-023-02406-x.